Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines

Experimental Cell Research

Volumn 249, Issue 1, 1999, Pages 109-115

  Hsieh, Tze chen ^a   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Androgen receptor (AR); Apoptosis; Prostate cell growth; Prostate specific antigen (PSA); Resveratrol

Indexed keywords

POLYPHENOL; RESVERATROL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL CYCLE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; WINE;

EID: 0033602719     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4471     Document Type: Article

References (35)

1. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics. CA Cancer J. Clin. 47:1997;5-27.
2. Hanks G. E., Myers C. E., Scardino P. T. Cancer: Principles and Practices of Oncology. 1993;Lippincott, Philadelphia. p. 1073-1113.
3. Isaacs J. T. Prostatic cancer: An age-old problem. Yang S. S., Warner H. R. The Underlying Molecular, Cellular, and Immunological Factors in Cancer and Aging. 1993;Plenum Press, New York.
4. Denmeade S. R., Lin X. S., Issacs J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 28:1996;251-265.
5. Muraki J., Addonizio J. C., Choudhury M. S., Fischer J., Eshghi M., Davidian M. M., Shapiro L. R., Wilmot P. L., Nagamatsu G. R., Chiao J. W. Establishment of new human prostatic cancer cell line (JCA-1). Urology. 36:1990;79-84.
6. Kaighn M. E., Narayan K. S., Ohnuki Y., Lechner J. F., Jones L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17:1979;16-23.
7. Stone K. R., Mickey D. D., Wunderli H., Mickey G. H., Paulson D. F. Isolation of a human prostate carcinoma cell line (DU-145). Int. J. Cancer. 21:1978;274-281.
8. Horoszewicz J. S., Leong S. S., Kawinski E., Karr J. P., Rosental H., Chu T. M., Mirand E. A., Murphy G. P. LNCaP model of human prostate carcinoma. Cancer Res. 43:1983;1809-1818.
9. Miller A. B. Diet and cancer: A review. Rev. Oncol. 3:1990;87-95.
10. Greenwald P., Kelloff G., Burch-Whitman C., Kramer B. S. Chemoprevention. CA Cancer J. Clin. 45:1995;31-49.
11. Hong W. K., Sporn M. B. Recent advances in chemoprevention of cancer. Science. 278:1997;1073-1077.
12. Jang M., Cai L., Udeani G. O., Slowing K. V., Thomas C. F., Beecher C. W. W., Fong H. H. S., Farnsworth N. R., Kinghorn D., Mehta R. G., Moon R. C., Pezzuto J. M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:1997;218-220.
13. Hsieh T. C., Wu J. M. Differential expression and regulation of p53 in human prostatic cells. Int. J. Oncol. 10:1997;1109-1112.
14. 3. Biochem. Biophys. Res. Commun. 235:1997;539-544.
15. Hsieh T. C., Wu J. M. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression. Prostate. 33:1997;97-104.
16. Hsieh T. C., Chiao J. W. Growth modulation of human prostatic cells by interleukin-1 and interleukin-1 receptor antagonists. Cancer Lett. 95:1995;119-123.
17. Hsieh T. C., Xu W., Chiao J. W. Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Exp. Cell Res. 218:1996;137-143.
18. Bedner E., Burfeind P., Hsieh T. C., Wu J. M., Aguero-Rosenfeld M. E., Melamed M. R., Horowitz H. W., Wormser G. P., Darzynkiewicz Z. Cell cycle effects and induction of apoptosis caused by infection of HL-60 cells with human granulocytic ehrlichiosis pathogen measured by flow and laser scanning cytometry. Cytometry. 33:1998;47-55.
19. Posadas E. M., Criley S. R., Coffey D. S. Chaotic oscillations in cultured cells: Rat prostate cancer. Cancer Res. 56:1996;3681-3688.
20. Doll R., Peto R. The causes of cancer: Quantitative estimates of avoidable risk of cancer in the United States. J. Natl. Cancer Inst. 66:1981;1191-1308.
21. Ames B. N., Gold L. S., Willett W. C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. USA. 92:1995;5258-5265.
22. Sporn M. B. Carcinogenesis and cancer: Different perspectives on the same disease. Cancer Res. 51:1991;6215-6218.
23. Soleas G. J., Diamandis E. P., Goldberg D. M. Resveratrol: A molecule whose time has come? And gone. Clin. Biochem. 30:1997;91-113.
24. Mgbonyebi O. P., Russo J., Russo I. H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol. 12:1998;865-869.
25. Fontecase M., Lepoivre M., Elleningand E., Gerez C., Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421:1998;277-279.
26. Sun N. J., Woo S. H., Cassady J. M., Snapka R. M. DNA polymerase and topoisomerase II inhibitors fromPsoralea corylifolia. J. Nat. Products. 61:1998;362-366.
27. Subbaramaiah K., Chung W. J., Michaluart P., Telang N., Tanabe T., Inoue H., Jang M., Pezzuto J. M., Dannenberg A. J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273:1998;21875-21882.
28. Gehm B. D., McAndrews J. M., Chien P. Y., Jameson J. L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA. 94:1997;14138-14143.
29. Kuiper G. G., Enmark E., Pelto H. M., Nilsson S., Gustafsson J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA. 93:1996;5925-5930.
30. Kelce W. R., Stone C. R., Lawe S. C., Gray L. E., Kemppainen J. A., Wilson E. M. Persistent DDT metabolitep,p. Nature. 375:1995;581-585.
31. Carruba G., Miceli M. D., Comito L., Farruggio R., Sorci C. M., Oliveri G., Amodio R., diFalco M., d'Amico D., Castagnetta L. A. Multiple estrogen function in human prostate cancer cells. Ann. N.Y. Acad. Sci. 784:1996;70-84.
32. Riegman P. H., Vlietstra R. J., van der Korput J. A., Brinkmann A. O., Trapman J. The promoter of the prostate specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 5:1991;1921-1930.
33. Montgomery B. T., Young C. Y., Bilhartz D. L., Andrews P. E., Prescott J. L., Thompson N. F., Tindall D. J. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate. 21:1992;63-73.
34. Lindzey M., Kumar M. V., Grossman M., Young C., Tindall D. J. Molecular mechanisms of androgen action. Vitamins Hormones. 49:1994;383-432.
35. Wang L. G., Liu X. M., Kreis W., Butman D. R. Involvement of prostate specific antigen in the stimulation of LNCaP cell growth. Oncol. Rep. 3:1996;911-917.